The Justice Department on Thursday announced that it was moving to ease restrictions on state-licensed medical marijuana, opening the door for more research and treatment options.

Acting Attorney General Todd Blanche said in a post to X that he had signed an executive order to immediately reschedule FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III and ordered an "expedited hearing" to fully reschedule the drug.

Schedule I drugs, which also include heroin, ecstasy and LSD, are considered to be more dangerous and are more strictly regulated, and advocates have had high hopes for cannabis to be rescheduled to a lower schedule.

Blanche said that the FDA-approved marijuana and state-licensed marijuana would now be classified as Schedule III, which is defined as "drugs with a moderate to low potential for physical and psychological dependence."

The Justice Department said in a press release that a June 29 hearing would “evaluate broader changes to marijuana’s status under federal law.”

“The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” Blanche said in a statement. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”

On Wednesday, a White House official told NBC News that the White House was working “expeditiously” to implement Trump’s executive order to ease restrictions on marijuana and increase medical research “to close the gap between current medical marijuana use and medical knowledge.”

Trump signed an executive order in December to fast-track cannabis reclassification. The move did not seek to legalize marijuana on the federal level.

Following the executive order, NBC News reported that scientists expressed high hopes that reclassifying cannabis would boost research possibilities, helping scientists better understand the drug’s impact on medical issues.

Cannabis was first established as a Schedule I drug during the Nixon administration.

NBC News has reached out to the White House for comment on the Justice Department's announcement.

This is a developing story. Please check back for updates.